BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 9127359)

  • 1. Genetic susceptibility for breast cancer: testing and primary prevention options.
    Baron RH; Borgen PI
    Oncol Nurs Forum; 1997 Apr; 24(3):461-8. PubMed ID: 9127359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic mastectomy and genetic testing: an update.
    Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
    Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting genetic testing and decisions about prophylactic surgery.
    Mahon SM
    Clin J Oncol Nurs; 2001; 5(3):117-20. PubMed ID: 11899370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attitudes and psychological impact of genetic testing, genetic counseling, and breast cancer risk assessment among women at increased risk.
    Hutson SP
    Oncol Nurs Forum; 2003; 30(2):241-6. PubMed ID: 12692658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The advanced practice nursing role in a high-risk breast cancer clinic.
    Vogel WH
    Oncol Nurs Forum; 2003; 30(1):115-22. PubMed ID: 12515989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevention of hereditary breast cancer.
    Rodriquez E; Domchek SM
    Semin Oncol; 2007 Oct; 34(5):401-5. PubMed ID: 17920894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
    Brunsvold AN; Wung SF; Merkle CJ
    J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
    Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation in breast cancer susceptibility testing protocols: influence of recruitment source, altruism, and family involvement on women's decisions.
    Geller G; Doksum T; Bernhardt BA; Metz SA
    Cancer Epidemiol Biomarkers Prev; 1999 Apr; 8(4 Pt 2):377-83. PubMed ID: 10207643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic predisposition testing: clinical implications for oncology nurses.
    Calzone KA
    Oncol Nurs Forum; 1997 May; 24(4):712-8. PubMed ID: 9159785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the breast cancer education and risk assessment program.
    Snyder LA; Soballe DB; Lahl LL; Nehrebecky ME; Soballe PW; Klein PM
    Oncol Nurs Forum; 2003; 30(5):803-8. PubMed ID: 12949593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.